Irsamla

Vortioxetine, the active ingredient in Irsamla, is a serotonin modulator and stimulator (SMI) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adults.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irsamla, a serotonin modulator and stimulator, is used in the management of depressive disorders.

- Major depressive disorder: improves depressive symptoms and functional outcomes in adult patients. - Persistent depressive symptoms: may be used as an adjunct when first‑line therapy is insufficient. - Relapse prevention: helps maintain remission after acute treatment response.

Vortioxetine is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate, often transient. - Headache: intermittent, may resolve with continued therapy. - Dizziness: usually mild, can be posture‑related. - Dry mouth: reduced salivation, manageable with hydration. - Constipation: occasional, responds to dietary fiber. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening when combined with other serotonergic agents. - Suicidal thoughts: increased risk especially at treatment initiation. - Severe hypertension: monitor blood pressure regularly. - Hyponatremia: low sodium levels, particularly in elderly patients. - Severe allergic reaction: rash, swelling, or anaphylaxis. - QT interval prolongation: rare cardiac conduction abnormality.

Before initiating Vortioxetine therapy, clinicians should consider several safety factors.

- Assess for suicidal ideation: monitor patients closely during the first weeks of treatment. - Avoid use with MAO inhibitors: ensure a minimum 14‑day washout period. - Caution in hepatic impairment: dose adjustment may be required for moderate to severe liver disease. - Monitor blood pressure: patients with pre‑existing hypertension should have regular readings. - Pregnancy and lactation: limited data; weigh potential benefits against unknown risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Vortioxetine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, triptans, linezolid, tramadol): may precipitate serotonin excess. - St. John’s wort: potentiates serotonergic activity.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., bupropion): may increase vortioxetine plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may require dose adjustment. - Alcohol: can enhance central nervous system depression. - Antihypertensives: possible additive blood‑pressure lowering effect. - NSAIDs: monitor for increased bleeding risk.